A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.

PHASE3CompletedINTERVENTIONAL
Enrollment

377

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

September 30, 2016

Study Completion Date

October 31, 2016

Conditions
Post-Ischemic Stroke
Interventions
DRUG

Placebo

DRUG

dalfampridine-ER 7.5mg

DRUG

dalfampridine-ER 10mg

Trial Locations (74)

10029

Acorda Site #172, New York

10605

Acorda Site #114, White Plains

11220

Acorda Site #102, New York

11772

Acorda Site #179, Patchogue

19001

Acorda Site #158, Abington

19104

Acorda Site #122, Philadelphia

20759

Acorda Site #175, Fulton

22310

Acorda Site #182, Alexandria

23298

Acorda Site #176, Richmond

27103

Acorda Site #132, Winston-Salem

27599

Acorda Site #166, Chapel Hill

27705

Acorda Site #167, Durham

28117

Acorda Site #162, Mooresville

30309

Acorda Site #186, Atlanta

32209

Acorda Site #143, Jacksonville

32611

Acorda Site #147, Gainesville

33012

Acorda Site #128, Hialeah

33064

Acorda Site #119, Deerfield Beach

33142

Acorda Site #103, Miami

33175

Acorda Site #133, Miami

33351

Acorda Site #145, Sunrise

33462

Acorda Site #115, Atlantis

33606

Acorda Site #106, Tampa

34102

Acorda Site #161, Naples

38163

Acorda Site #157, Memphis

40513

Acorda Site #146, Lexington

43210

Acorda Site #137, Columbus

44195

Acorda Site #160, Cleveland

44811

Acorda Site #187, Bellevue

45417

Acorda Site #116, Dayton

46123

Acorda Site #148, Avon

46131

Acorda Site #156, Franklin

46805

Acorda Site #188, Fort Wayne

48025

Acorda Site #164, Bingham Farms

48201

Acorda Site #127, Detroit

48824

Acorda Site #123, East Lansing

49503

Acorda Site #159, Grand Rapids

59405

Acorda Site #111, Great Falls

60611

Acorda Site #171, Chicago

64132

Acorda Site #101, Kansas City

70121

Acorda Site #150, New Orleans

75214

Acorda Site #113, Dallas

75246

Acorda Site #165, Dallas

77030

Acorda Site #108, Houston

80907

Acorda Site #124, Colorado Springs

85234

Acorda Site #117, Gilbert

89502

Acorda Site #140, Reno

90806

Acorda Site #138, Long Beach

91105

Acorda Site #142, Pasadena

92056

Acorda Site #170, Oceanside

92103

Acorda Site #151, San Diego

92123

Acorda Site #163, San Diego

92663

Acorda Site #105, Newport Beach

94705

Acorda Site #109, Berkeley

95823

Acorda Site #153, Sacramento

96734

Acorda Site #181, Kailua

97225

Acorda Site #168, Portland

97239

Acorda Site #126, Portland

97330

Acorda Site #152, Corvallis

276076010

Acorda Site #154, Raleigh

992021330

Acorda Site #107, Spokane

06810

Acorda Site #110, Danbury

06824

Acorda Site #149, Fairfield

06905

Acorda Site #130, Stamford

02114

Acorda Site #136, Boston

02118

Acorda Site #121, Boston

016052610

Acorda Site #120, Worcester

08903

Acorda Site #131, New Brunswick

08084

Acorda Site #177, Stratford

02903

Acorda Site #144, Providence

E3B0C7

Acorda Site #203, Fredericton

B3H4K4

Acorda Site #202, Halifax

J4V2G9

Acorda Site #201, Greenfield Park

H3G1A4

Acorda Site #204, Montreal

Sponsors
All Listed Sponsors
lead

Acorda Therapeutics

INDUSTRY

NCT02271217 - A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets. | Biotech Hunter | Biotech Hunter